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Abstract
Background: Everolimus-eluting bioresorbable vascular scaffolds (BVS) represent an innovative treatment option for
coronary artery disease. Clinical and angiographic results seem promising, however, data on its immediate procedural
performance are still scarce. The aim of our study was to assess the mechanical properties of BVS by Optical Coherence
Tomography (OCT) in clinical routine.
Methods: Post-implantation OCT images of 40 BVS were retrospectively compared to those of 40 metallic
everolimus-eluting stents (EES). Post-procedural device related morphological features were assessed. This
included incidences of gross underexpansion and the stent eccentricity index (SEI, minimum/maximum diameter)
as a measure for focal radial strength.
Results: Patients receiving BVS were younger than those with EES (54.0 ± 11.2 years versus 61.7 ± 11.4 years, p = 0.012),
the remaining baseline, vessel and lesion characteristics were comparable between groups. Lesion pre-dilatation was
more frequently performed and inflation time was longer in the BVS than in the EES group (n = 34 versus n = 23, p = 0.
006 and 44.2 ± 12.8 versus 25.6 ± 8.4 seconds, p < 0.001, respectively). There were no significant differences in maximal
inflation pressures and post-dilatation frequencies with non-compliant balloons between groups. Whereas gross device
underexpansion was not significantly different, SEI was significantly lower in the BVS group (n = 12 (30 %) versus n = 14
(35 %), p = 0.812 and 0.69 ± 0.08 versus 0.76 ± 0.09, p < 0.001, respectively). There was no difference in major adverse
cardiac event-rate at six months.
Conclusion: Our data show that focal radial expansion was significantly reduced in BVS compared to EES in a clinical
routine setting using no routine post-dilatation protocol. Whether these findings have impact on scaffold mid-term
results as well as on clinical outcome has to be investigated in larger, randomized trials.
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Background
Drug eluting stents (DES) have shown to be highly ef-
fective in the treatment of patients with coronary artery
disease [1–3] as neointimal hyperplasia after a vascular
injury was reduced compared to when bare metal stents
were used [2, 3]. Nevertheless, delayed or absent strut
endothelialization, persistent or acquired malapposition
and neoatherosclerosis of DES contribute to late stent
failure rates which are in the range of 1-2 % a year
within the first three years after implantation [4–6]. In
addition stent fractures especially at hinge points of the
coronary vessels and the lack of adaptive remodelling
processes in the artery wall can contribute to late events.
Bioresorbable vascular scaffolds (BVS) were developed
in order to reduce those potential adverse events after a
coronary intervention. After the bioresorption process is
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completed there will not be any potential triggers for
late adverse events [7]. In contrast to vessels caged by
metallic stents, vessels transiently scaffolded by biore-
sorbable materials are able to perform vasoconstriction
and vasodilation and therefore could also contribute to
better symptom control in patients with coronary artery
disease [8–11]. It was also shown that BVS are charac-
terized by a better conformability to the vessel compared
to metallic stents [12]. On the other hand it is still un-
clear if the radial strength provided by BVS is sufficient
throughout various clinical scenarios. It has been shown
that metallic stents generate a larger acute lumen gain
compared to BVS, but scaffold/stent type was not pre-
dictive for acute recoil [13]. Intravascular imaging data
describing device strength and expansion are still scarce.
The aim of the present study was to assess the mechan-
ical properties of BVS by Optical Coherence Tomog-
raphy (OCT) in clinical routine.
Methods
Patients
Between March and June 2013, 26 consecutive patients
underwent OCT immediately after implantation of 40
BVS (Absorb, Abbott Vascular, Santa Clara, CA, USA).
Elective patients as well as patients presenting with acute
coronary syndrome (ACS) were included. The OCT data
of these patients were retrospectively compared with
those of 34 consecutive patients after implantation of
40 metallic everolimus-eluting stents (EES, Xience, Abbott
Vascular, Santa Clara, CA, USA).
Patient characteristics were collected from the medical
records of each patient, device characteristics and deploy-
ment strategies were collected from the database of the
cardiac catheter laboratory. This study was approved by
the ethics committee of the Medical University of Vienna
and all patients gave their written informed consent.
Definitions
Stent eccentricity index (SEI): at the site of minimal
lumen area (MLA) stent eccentricity index, defined as
the ratio between minimal and maximal diameter, was
calculated [14].
Stent symmetry index (SSI): at the site of MLA stent
symmetry index, defined as (maximal-minimal diameter)/
maximal diameter, was calculated [14].
Underexpansion: a stent was considered underexpanded
if MLA was ≤ 80 % of average reference lumen area [15].
Plaque characteristics: plaque type was determined at
proximal and distal stent ending, as well as at MLA
and was considered to be either lipid-rich, fibrous or
fibro-calcific [16].
Incomplete stent apposition (ISA): struts were considered
incompletely apposed when they were separated from the
underlying vessel wall in case of BVS [17] or when the axial
distance between strut's surface and the luminal surface
was greater than the strut thickness in case of EES [18].
OCT - acquisition and analysis
Patients were pre-treated with a dual antiplatelet therapy,
a weight-adjusted intravenous bolus of unfractionated
heparin, and 200 μg intracoronary nitroglycerine. The
OCT images were obtained using a frequency domain
(FD) - OCT system (LightLab Imaging, Inc., Westford,
MS, USA). The FD-OCT imaging catheters were deliv-
ered over a 0.014-inch (0.0356 cm) guide wire through
a 6-F guiding catheter. Images were acquired using a
motorized pullback system at a speed of 36 mm/s during a
flush of 4 to 6 ml/s of iso-osmolar contrast (Iodixanol 320,
VisipaqueTM, GE Health Care, Cork, Ireland) through the
guiding catheter to replace the blood flow and permit the
visualization of the stented segment and intima-lumen
interface. Whenever the stented segment was too long to
be completely imaged in a single pullback, the image
acquisition was repeated from the same position during
a second contrast injection. Anatomic landmarks such as
side branches, calcifications or stent overlap segments
were used for longitudinal view orientation.
OCT imaging was performed after what was deemed
to be an angiographically successful intervention at the
operator’s discretion. All OCT frames were digitally stored
and independently analyzed using an offline software
(LightLab Console) by one operator, who is experienced in
and familiar with assessing OCT images. Cross-sections
within the stented segment were analyzed every frame.
Statistical analysis
The statistical analysis was conducted with SPSS® Sta-
tistics 21.0 (SPSS Inc, Chigago, USA). Quantitative data
were presented as mean ± standard deviation. Qualitative
data were presented as frequencies. Categorical variables
were assessed by χ2 statistics and Fisher's exact test. Con-
tinuous variables were compared using an unpaired t-test.
A p-value <0.05 was considered statistically significant.
Results
Patients receiving BVS were younger than those with
EES (54.0 ± 11.2 years vs. 61.7 ± 11.4 years, p = 0.012)
and were smokers less frequently. The remaining base-
line characteristics were comparable between the two
groups (Table 1). The majority of treated lesions in both
groups were simple lesions (type B1, 62 % in BVS vs.
70 % in EES group, p = 0.407).
Device and procedural characteristics are depicted in
Table 2. Pre-dilatation was more frequently performed
before BVS implantation and the diameter of the pre-
dilatation balloon was larger in the BVS group (85 % vs.
58 %, p = 0.006 and 2.64 ± 0.51 mm vs. 2.34 ± 0.46 mm,
p = 0.026, respectively), while BVS diameters were larger
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compared to those of EES (3.23 ± 0.34 mm vs. 3.07 ±
0.54 mm, p = 0.124). Lesion diameter stenosis was less
severe in the BVS group and the inflation time was lon-
ger (81 ± 14 % vs. 89 ± 14 %, p = 0.023 and 44 ± 13 sec
vs. 26 ± 8 sec, p < 0.001, respectively).
OCT results
OCT analysis (Table 3) showed comparable plaque com-
positions between the two groups at the proximal and
distal stent endings as well as at the point of minimal
lumen area. Although there were no statistically signifi-
cant differences in the minimal lumen area and in the
incidence of device underexpansion between the groups
(6.38 ± 2.00 mm2 vs. 6.42 ± 2.42 mm2, p = 0.662 and
30 % vs. 35 %, p = 0.812, respectively) the SEI at the site
of the minimal lumen area was significantly lower in the
BVS group compared to EES (0.69 ± 0.08 vs. 0.76 ± 0.09,
p < 0.001). SSI was significantly higher in BVS compared
to EES (0.30 ± 0.09 vs. 0.23 ± 0.09, p < 0.001).
Clinical follow-up
After six months there was no detectable difference in
major adverse cardiac event (MACE) rate between
groups (Table 4). One patient in the BVS group under-
went angiography after three months because of recur-
rent angina. Subacute thrombotic lesions were
angiographically revealed and thrombus aspiration fol-
lowing dilatation with a non-compliant balloon was per-
formed. One patient in the EES group was re-admitted
due to unstable angina after 45 days. Angiography showed
an intima-flap at the proximal stent ending which resulted
in another overlapping stent-implantation. Another EES
patient underwent elective angiography after three
months. Although he presented free of any symptoms EES
Table 2 Device and procedural characteristics
BVS (n = 40) EES (n = 40) P-value
Nominal diameter, mm 3.23 ± 0.34 3.07 ± 0.54 0.124
Length, mm 21.80 ± 5.62 21.13 ± 9.21 0.693
Stenosis, % 81 ± 14 89 ± 14 0.023
Inflation time, sec 44 ± 13 26 ± 8 <0.001
Inflation pressure, atm 13 ± 3 13 ± 3 0.799
Predilatation, n (%) 34 (85) 23 (58) 0.006
Predilatation-ballon diameter, mm 2.64 ± 0.51 2.34 ± 0.46 0.026
Predilatation-ballon inflation pressure, atm 13 ± 2 12 ± 3 0.266
Postdilatation, n (%) 22 (55) 27 (68) 0.179
Postdilatation-ballon diameter, mm 3.41 ± 0.47 3.27 ± 0.60 0.380
Postdilatation-ballon inflation pressure, atm 15 ± 3 16 ± 4 0.282
Postdilatation with NC-ballon, n (%) 21 (53) 16 (40) 0.321
Contrast volume, ml 215.2 ± 150.9 213.9 ± 96.8 0.963
Radiation time, min 12.1 ± 9.2 11.8 ± 6.5 0.874
CX Circumflex Artery, LAD Left Anterior Descending Artery, LM Left Main, NC Non-Compliant, RCA Right Coronary Artery
Table 1 Baseline characteristics
BVS (n = 26) EES (n = 34) P-value
Age, years 54.0 ± 11.2 61.7 ± 11.4 0.012
Male, n (%) 19 (73) 30 (88) 0.122
Diabetes
No, n (%) 18 (69) 25 (74)
NIDDM, n (%) 5 (19) 9 (26) 0.117
IDDM, n (%) 3 (12) 0
Hypertension, n (%) 15 (58) 25 (74) 0.156
Hyperlipidemia, n (%) 17 (65) 21 (62) 0.494
Positive family history, n (%) 6 (23) 10 (29) 0.402
Smoking
No, n (%) 15 (58) 9 (26)
Ex, n (%) 2 (8) 13 (38) 0.011
Current, n (%) 9 (34) 12 (36)
Indication for PCI
ACS - STEMI, n (%) 3 (12) 1 (3)
ACS - NSTEMI, n (%) 7 (27) 6 (18) 0.237
Non-ACS elective, n (%) 16 (61) 27 (79)
LAD, n (%) 19 (73) 19 (56)
CX, n (%) 3 (11) 9 (26) 0.261
RCA, n (%) 4 (15) 5 (15)
Ramus intermedius, n (%) 1 (5) 0
Lesion classification
Type B1, n (%) 16 (62) 24 (70)
Type B2, n (%) 5 (19) 5 (15) 0.407
Type C, n (%) 5 (19) 5 (15)
ACS Acute Coronary Syndrome, IDDM Insulin Dependent Diabetes Mellitus,
NIDDM Non-Insulin Dependent Diabetes Mellitus, NSTEMI Non-ST Elevation
Myocardial Infarction, STEMI ST Elevation Myocardial Infarction
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showed significant in-stent-restenosis which was fixed by
drug-eluting balloon dilatation.
Discussion
Whereas BVS were rapidly adopted in clinical routine,
prospective data especially with regard to complex le-
sions are still rare [19–21]. Recent data suggest that
acute and late stent thrombosis are more frequent in
BVS compared to DES [22], which is potentially associated
with the unique mechanical properties of BVS. It has
been shown that OCT is a valuable tool in determining
post-procedural success with both BVS and DES as it
potentially reduces late complications caused by mech-
anical shortcomings of the devices not detected when
using angiography. This is the first OCT study compar-
ing BVS and EES in a clinical routine setting.
Table 3 OCT analysis
BVS (n = 40) EES (n = 40) P-value
Plaque type distal stent ending
Lipid rich, n (%) 21 (53) 20 (50)
Fibrous, n (%) 17 (42) 15 (38) 0.493
Fibro-calcific, n (%) 2 (5) 5 (12)
Plaque type proximal stent ending
Lipid rich, n (%) 23 (58) 15 (38)
Fibrous, n (%) 8 (20) 12 (30) 0.114
Fibro-calcific, n (%) 9 (22) 13 (32)
Plaque type MLA
Lipid rich, n (%) 20 (50) 18 (45)
Fibrous, n (%) 8 (20) 8 (20) 0.826
Fibro-calcific, n (%) 8 (20) 12 (30)
Plaque rupture - hematoma, n (%) 4 (10) 2 (5)
Reference vessel area distal, mm2 6.40 ± 2.11 6.49 ± 2.57 0.879
Reference vessel diameter distal, mm 2.78 ± 0.49 2.80 ± 0.64 0.854
Reference vessel area proximal, mm2 8.98 ± 2.55 9.43 ± 4.15 0.560
Reference vessel diameter proximal, mm 3.37 ± 0.51 3.44 ± 0.76 0.631
Reference vessel area, mm2 7.69 ± 2.17 7.96 ± 3.30 0.668
Reference vessel diameter, mm 3.07 ± 0.44 3.09 ± 0.62 0.834
Distal stent ending area, mm2 6.77 ± 2.34 6.97 ± 2.75 0.721
Distal stent ending diameter, mm 2.88 ± 0.53 2.92 ± 0.56 0.750
Proximal stent ending area, mm2 7.48 ± 2.35 8.62 ± 3.51 0.092
Proximal stent ending diameter, mm 3.04 ± 0.49 3.25 ± 0.63 0.102
Difference nominal diameter-proximal stent ending diameter, mm 0.19 ± 0.37 - 0.18 ± 0.52 <0.001
Mean stent area, mm2 7.12 ± 2.20 7.79 ± 2.30 0.257
Mean stent diameter, mm 2.96 ± 0.48 3.08 ± 0.57 0.984
Minimal lumen area, mm2 6.38 ± 2.00 6.42 ± 2.42 0.662
Minimal stent diameter, mm 2.46 ± 0.43 2.53 ± 0.54 0.537
Maximal stent diameter, mm 3.53 ± 0.52 3.31 ± 0.64 0.085
Stent eccentricity index 0.69 ± 0.08 0.76 ± 0.09 <0.001
Stent symmetry index 0.30 ± 0.09 0.23 ± 0.09 <0.001
RAS, % 16.99 ± 12.86 17.70 ± 11.50 0.795
Rate of ISA, % 3.4 ± 1.9 2.9 ± 1.9 0.720
Underexpansion, n (%) 12 (30) 14 (35) 0.812
Underexpansion & hematoma, n (%) 1 (3) 1 (3) 1.000
Stent fracture, n (%) 3 (8) 0 0.241
ISA Incomplete Stent Apposition, MLA Minimal Lumen Area, RAS Residual Area Stenosis
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The main finding of this study was that in a routine
setting using no post-dilatation protocol, although gross
device expansion of BVS and EES was comparable, de-
vice expansion uniformity of BVS, defined by SEI at the
point of MLA, was significantly lower, whereas SSI was
higher in BVS compared to EES (Fig. 1).
This lower device expansion can potentially contribute
to an alteration in blood flow dynamics and can therefore
represent a source for acute and subacute post-procedural
complications as shown by Otake and coworkers [23].
Interestingly, this finding contradicts the study of Matte-
sini [14] but is in line with that of Brugaletta and co-
workers in a substudy of the Absorb cohort B trial [24].
The most plausible explanation is that in the study of
Mattesini a more aggressive vessel preparation with a
balloon/artery ratio 1:1 and a stringent OCT guided
post-dilatation balloon inflation strategy with non-compliant
balloons were performed. In our study pre-dilatation was
performed with in average 0.5 mm undersized balloons in
85 % of all cases and post-dilatation with NC-balloons was
done only in 55 % of BVS implantations which is closer to
the treatment procedure used in in the Absorb cohort B
trial. Accordingly post-dilatation was performed in only
50 % of cases in the Ghost-EU trial, which included 1189 pa-
tients [25]. It is noteworthy that especially in the early phase
the incidences of scaffold thrombosis were more frequent
than anticipated in this study, which may be influenced by
the low rates of post-dilatation (<40 %) in these patients with
BVS failure. Although the lack of a stringent post-dilatation
protocol is the most plausible cause for the discussed differ-
ences in SEI other contributing factors have to be consid-
ered. In contrast to our study, in which patients with ACS
represented > 1/3 of the study population, they were not in-
cluded in the study of Mattesini. In patients presenting with
ACS, previous imaging analysis found more complex lesion
morphologies when compared to patients with stable CAD
[26]: Especially developing intramural hemorrhages is more
common in acute lesions and because of the limited radial
strength of BVS [13] they might not be able to withstand
the consecutively increased vessel wall resistance (Fig. 2).
The different post-procedural stent geometry was also
supported by significant differences in the nominal vessel/
proximal device ending diameter, where the proximal BVS
ending was in average smaller and the proximal EES was
in average larger than the native vessel diameter. This
finding is in accordance with the study of Mattesini, where
ISA at the proximal edge was more frequently observed in
the BVS group. Although the clinical significance of ISA is
not definitely determined, it has been associated with stent
thrombosis in IVUS studies [27, 28]. In addition pro-
truding struts at the proximal edge may complicate the
advancement of other devices distal of the stent. How-
ever compared to DES the bioabsorbable technology
has the potential advantage of ISA being at least only a
temporary problem.
Limitations
This is a retrospective, single center, non-randomized ob-
servational study in a limited number of patients. Although
patient characteristics were well matched no propensity
adjustments have been performed. Final OCT assessment
was performed, when the operators deemed to be angio-
graphically successful, which provides a potential bias.
Table 4 Six months clinical follow-up
BVS (n = 26) EES (n = 34) P-value
MACE, n (%) 1 (4) 2 (6) 1.000
Death, n (%) 0 0
MI, n (%) 0 0
TV-Revasc., n (%) 1 (4) 2 (6) 1.000
Non-TV-Revasc. n (%) 0 0
MACE Major Adverse Cardiac Event, MI Myocardial Infarction, TV Target Vessel,
Revasc - Revascularization
Fig. 1 Automatic measurements performed at site of minimal lumen area in BVS (a) and EES (b)
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Nevertheless in the learning curve of a new technology
it is of high value to identify potential safety concerns
additionally to large randomized trials in clinical studies.
In our routine setting we could reveal significant differ-
ences in the post-procedural geometry between BVS and
EES using OCT. Whether these differences may contribute
to the somewhat higher stent thrombosis rates observed in
other series remains unclear. To avoid inappropriate BVS
expansion it seems advisable to incorporate routine post-
dilatation with NC-balloons in the procedural protocol.
The role of aggressive pre-dilatation with its potential com-
plications remains a matter of debate and the use of intra-
vascular imaging may further delineate the appropriate use
of BVS.
Conclusion
Although minimal lumen areas and rates of device under-
expansion were comparable between BVS and EES, local
radial expansion is significantly reduced in BVS in a clinical
routine setting using no post-dilatation protocol. The clin-
ical importance of this finding remains unclear and has to
be evaluated in larger, randomized trials. However, a lower
uniform expansion of the BVS could contribute to clinical
events such as scaffold thrombosis and should be consid-
ered when implanting these devices. Considering the rela-
tively low number of post-dilatations with non-compliant
balloons in the BVS group our data further suggest that
routine post-dilatation should be strongly considered.
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